ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01319370
Recruitment Status : Completed
First Posted : March 21, 2011
Last Update Posted : November 7, 2013
Sponsor:
Collaborator:
Johnson & Johnson
Information provided by (Responsible Party):
Natalie GARCIA BARTELS, Charite University, Berlin, Germany

Brief Summary:
The current study aims to show efficacy of twice daily application of 5% Minoxidil Topical Foam (MTF) formulation compared to placebo in the temple region of male patients with androgenetic alopecia after 24 weeks as well as to gain long-term data on the efficacy and safety of 5% MTF in male subjects with AGA in temple and vertex region, over a period of 2 years. Objective and subjective efficacy measures will be compared to baseline. Moreover, all patients will get the equal treatment and measurements in the vertex region to enable comparison of the efficacy of 5% Minoxidil Topical Foam in the temples not only to baseline but also to vertex region. Additionally safety assessments will be performed throughout the whole study.

Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Drug: Minoxidil Drug: vehicle of 5% Minoxidil topical foam Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks
Study Start Date : November 2010
Actual Primary Completion Date : March 2013
Actual Study Completion Date : March 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Minoxidil

Arm Intervention/treatment
Placebo Comparator: vehicle of 5% Minoxidl topical foam
vehicel foam in twice daily application in temple and vertex region
Drug: vehicle of 5% Minoxidil topical foam
1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase

Active Comparator: 5% Minoxidil topical foam
5% Minoxidil topical in twice daily application in temple and vertex region
Drug: Minoxidil
1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase




Primary Outcome Measures :
  1. Change of target area non-vellus hair count in the temple region (t-TAHC) [n/cm²] compared to baseline after 24 weeks [ Time Frame: Baseline, week 8, week 16, week 24, week 52, week 76, week 104 ]

Secondary Outcome Measures :
  1. Assessing the investigational products safety by means of clinical examination (local intolerance, AE, SAE) [ Time Frame: every visit from baseline to week 104 ]
  2. Change of cumulative hair width in non-vellus hair in temple and vertex region (t-TAHW; v-TAHW) [mm/cm²] compared to baseline after 24, 52, 76 and 104 weeks [ Time Frame: Baseline, week 8, week 16, week 24, week 52, week 76, week 104 ]
  3. Change of t-TAHC, v-TAHC, t-TAHW and v-TAHW comparing 5% MTF and Placebo Topical Foam (plaTF) groups [ Time Frame: Baseline, week 8, week 16, week 24, week 52, week 76, week 104 ]
  4. Global expert panel and subjects' rating change in scalp coverage: week 24 compared to baseline, week 104 compared to baseline and week 104 compared to week 24 via assessment of global temple and vertex photographs [ Time Frame: Baseline, week 8, week 16, week 24, week 52, week 76, week 104 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male, age 18 to 70 year old, in general good health
  • Exhibits male AGA based on a discernable hair loss in temple and vertex region rating Hamilton-Norwood Scale III vertex to VI (See Appendix 1)
  • Subjects who give their consent to the study after thorough explanation and who personally signed and dated the informed consent document indicating that the subject, has been informed of all pertinent aspects of the trial
  • Willing to maintain the same hairstyle, hair length and hair color throughout the study
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, mini-tattoo and other trial procedures
  • Accepting the Information form plus accepting and signing the Informed Consent form

Exclusion Criteria:

  • Known to be hypersensitive to minoxidil, hair dye (p-phenylenediamine), tattoo ink, fragrances, hair gel or any vehicle components
  • Current or 4 weeks dated back use of medical shampoos or solutions which include Ketoconazole or the like (e. g. Terzolin®) in the target region interfering with the CTM or examination method
  • Current or 3 months dated back use of topical treatment in the target regions taken for more then 2 consecutive weeks interfering with the CTM (topical corticosteroids, aminexil, minoxidil, estrogens)
  • Current or 3 months dated back use of systemic treatment (drugs or dietary supplement) taken for more than 2 consecutive weeks interfering with the CTM or examination method (beta blocker, cimetidine, diazoxide, isotretionin, corticosteroids, vitamin A intake above 10000 IU per day)
  • Current or 12 months dated back use of Finasteride (Propecia®, FinaHair®, etc.), Dutasteride or a similar product
  • Within past 12 months undergoing chemotherapy or receiving cytotoxic agents as well as radiation and/or laser/surgical therapy of the scalp
  • Current or prior enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation
  • Presence of hair transplants, hair weaves or non-breathable wigs and hair bonding
  • Current or 2 months dated back severe diet or presenting a history of eating disorder
  • Any dermatological disorders of the scalp in the target region with the possibility of interfering with the CTM or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars or scalp atrophy
  • Untreated persisting hypertension
  • Active hair loss or history within the past 3 months including diffuse telogen effluvium, alopecia areata, scarring alopecia
  • Other severe, acute or chronic medical condition that may lead to hair loss or interfere with the interpretation of trial results (e. g. untreated hypothyroidism)
  • Individuals who are institutionalized by court or regulatory order

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01319370


Locations
Germany
Charité-Universitätsmedizin Berlin, Clinical Research Center for Hair and Skin Science, Dept. of Dermatology, Venereology and Allergy
Berlin, Germany, 10117
Sponsors and Collaborators
Natalie GARCIA BARTELS
Johnson & Johnson

Responsible Party: Natalie GARCIA BARTELS, PD, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT01319370     History of Changes
Other Study ID Numbers: CRC-AGA02
2010-018291-25 ( EudraCT Number )
First Posted: March 21, 2011    Key Record Dates
Last Update Posted: November 7, 2013
Last Verified: November 2013

Additional relevant MeSH terms:
Alopecia
Alopecia Areata
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Minoxidil
Antihypertensive Agents
Vasodilator Agents